帕金森病
阿扑吗啡
医学
多巴胺能
多巴胺受体
兴奋剂
多巴胺激动剂
普拉克索
多巴胺受体D2
单光子发射计算机断层摄影术
内科学
左旋多巴
多巴胺
帕金森病
疾病
受体
作者
Joshua P. Schwarz,Klaus Tatsch,Gabriele Arnold,T. Gasser,Claudia Trenkwalder,Carl-Martin Kirsch,W. H. Oertel
出处
期刊:Neurology
[Ovid Technologies (Wolters Kluwer)]
日期:1992-03-01
卷期号:42 (3): 556-556
被引量:135
摘要
We used 123 I-iodobenzamide-single photon emission computed tomography (IBZM-SPECT) in a prospective study to investigate 38 patients with parkinsonism (Hoehn and Yahr stage I to III) not previously treated with dopamimetic drugs. Thirty-four patients only showed symptoms of Parkinson's disease, and four patients showed, in addition, subtle clinical signs of progressive supranuclear palsy or multisystem atrophy. IBZM is a dopamine D2 receptor antagonist detectable by SPECT. We compared IBZM-SPECT results with clinical response to subcutaneous injections of the D1/D2 dopamine receptor agonist apomorphine (38 patients) and long-term dopamimetic therapy (31 patients). IBZM-SPECT results predicted a positive or negative response to apomorphine in 30 of 34 patients (apomorphine response in four patients was equivocal) and response to dopamimetic therapy in 27 of 31 patients. Thus, imaging of dopamine D2 receptors using readily available IBZM-SPECT seems to distinguish between L-dopa-responsive (most likely Parkinson's disease of Lewy body type) and L-dopa-unresponsive parkinsonism in patients not previously treated with dopamimetic drugs.
科研通智能强力驱动
Strongly Powered by AbleSci AI